Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 5
2009 4
2010 12
2011 4
2012 11
2013 26
2014 23
2015 18
2016 14
2017 11
2018 7
2019 10
2020 3
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Michaeli DT, et al. Am J Cardiovasc Drugs. 2023 Sep;23(5):477-495. doi: 10.1007/s40256-023-00594-5. Epub 2023 Jul 24. Am J Cardiovasc Drugs. 2023. PMID: 37486464 Free PMC article. Review.
Recent biotechnological advances have led to the development of innovative small molecules (bempedoic acid, lomitapide, pemafibrate, docosapentaenoic and eicosapentaenoic acid), antibodies (evinacumab), antisense oligonucleotides (mipomersen, volanesorsen, pelcarsen, oleza …
Recent biotechnological advances have led to the development of innovative small molecules (bempedoic acid, lomitapide, pemafibrate, docosap …
Mipomersen sodium: first global approval.
Hair P, Cameron F, McKeage K. Hair P, et al. Drugs. 2013 Apr;73(5):487-93. doi: 10.1007/s40265-013-0042-2. Drugs. 2013. PMID: 23564617 Review.
Mipomersen sodium (Kynamro) (henceforth mipomersen) is a second-generation antisense oligonucleotide inhibitor of apolipoprotein B-100, which is the main structural component of atherogenic lipid particles. Mipomersen is administered via subcutaneous injectio …
Mipomersen sodium (Kynamro) (henceforth mipomersen) is a second-generation antisense oligonucleotide inhibitor of apolipoprote …
Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Alhamadani F, Zhang K, Parikh R, Wu H, Rasmussen TP, Bahal R, Zhong XB, Manautou JE. Alhamadani F, et al. Drug Metab Dispos. 2022 Jun;50(6):879-887. doi: 10.1124/dmd.121.000418. Epub 2022 Feb 27. Drug Metab Dispos. 2022. PMID: 35221289 Free PMC article. Review.
Although ASO drugs are efficacious in treating some diseases that are untargetable by small-molecule chemical drugs, concerns on adverse drug reactions (ADRs) and toxicity cannot be ignored. Illustrative of this, mipomersen was recently taken off the market due to its hepa …
Although ASO drugs are efficacious in treating some diseases that are untargetable by small-molecule chemical drugs, concerns on adverse dru …
Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
Patel N, Hegele RA. Patel N, et al. Expert Opin Pharmacother. 2010 Oct;11(15):2569-72. doi: 10.1517/14656566.2010.512006. Expert Opin Pharmacother. 2010. PMID: 20707601 Review.
In addition, mipomersen lowered plasma lipoprotein (a). In most patients, mipomersen administration was most associated with injection-site reactions; influenza-like symptoms were also more common in mipomersen-treated patients. ...Despite these promising res …
In addition, mipomersen lowered plasma lipoprotein (a). In most patients, mipomersen administration was most associated with i …
Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Bell DA, Hooper AJ, Burnett JR. Bell DA, et al. Expert Opin Investig Drugs. 2011 Feb;20(2):265-72. doi: 10.1517/13543784.2011.547471. Epub 2011 Jan 6. Expert Opin Investig Drugs. 2011. PMID: 21210756 Review.
AREAS COVERED: the mode of action, preclinical development and clinical trials of mipomersen, an antisense apoB synthesis inhibitor. The paper provides an understanding of the pharmacokinetic and pharmacodynamic characteristics of mipomersen and insight into its cli …
AREAS COVERED: the mode of action, preclinical development and clinical trials of mipomersen, an antisense apoB synthesis inhibitor. …
Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.
Blom DJ, Raal FJ, Santos RD, Marais AD. Blom DJ, et al. Curr Atheroscler Rep. 2019 Nov 19;21(12):48. doi: 10.1007/s11883-019-0809-3. Curr Atheroscler Rep. 2019. PMID: 31741187 Review.
PURPOSE OF REVIEW: The goal of this review is to evaluate the role of inhibiting the synthesis of lipoproteins when there is no or little residual LDL-receptor function as in patients with homozygous familial hypercholesterolaemia. Lomitapide is administered orally once a day whi …
PURPOSE OF REVIEW: The goal of this review is to evaluate the role of inhibiting the synthesis of lipoproteins when there is no or little re …
Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials.
Li N, Li Q, Tian XQ, Qian HY, Yang YJ. Li N, et al. Am J Cardiovasc Drugs. 2014 Oct;14(5):367-76. doi: 10.1007/s40256-014-0077-0. Am J Cardiovasc Drugs. 2014. PMID: 25027352 Review.
OBJECTIVE: This study sought to ascertain both the extent to which mipomersen can decrease ApoB-containing lipoproteins and the safety of mipomersen therapy. ...Future studies exploring how to minimize side effects of mipomersen therapy are needed....
OBJECTIVE: This study sought to ascertain both the extent to which mipomersen can decrease ApoB-containing lipoproteins and the safet …
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
Bell DA, Hooper AJ, Watts GF, Burnett JR. Bell DA, et al. Vasc Health Risk Manag. 2012;8:651-9. doi: 10.2147/VHRM.S28581. Epub 2012 Nov 28. Vasc Health Risk Manag. 2012. PMID: 23226021 Free PMC article. Review.
Mipomersen has been shown to decrease apoB, LDL-cholesterol and lipoprotein(a) in patients with heterozygous and homozygous FH on maximally tolerated lipid-lowering therapy. The short-term efficacy and safety of mipomersen has been established, however, injection si …
Mipomersen has been shown to decrease apoB, LDL-cholesterol and lipoprotein(a) in patients with heterozygous and homozygous FH on max …
Is mipomersen ready for clinical implementation? A transatlantic dilemma.
Sjouke B, Balak DM, Beuers U, Ratziu V, Stroes ES. Sjouke B, et al. Curr Opin Lipidol. 2013 Aug;24(4):301-6. doi: 10.1097/MOL.0b013e328362dfd9. Curr Opin Lipidol. 2013. PMID: 23759796 Review.
Although long-term studies with mipomersen are eagerly awaited, hepatic fat content appears to stabilize after 6-12 months notwithstanding continued mipomersen administration. ...No evidence is available suggesting that injection site reactions because of mipomer …
Although long-term studies with mipomersen are eagerly awaited, hepatic fat content appears to stabilize after 6-12 months notwithsta …
Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes.
Chambergo-Michilot D, Alur A, Kulkarni S, Agarwala A. Chambergo-Michilot D, et al. Vasc Health Risk Manag. 2022 Feb 21;18:73-80. doi: 10.2147/VHRM.S191965. eCollection 2022. Vasc Health Risk Manag. 2022. PMID: 35221690 Free PMC article. Review.
Once administered, mipomersen causes selective degradation of the apoB-100 mRNA and inhibition of protein translation. This ultimately results in substantial reductions in LDL-C and other lipoprotein levels. Mipomersen is approved for the treatment of homozygous FH. …
Once administered, mipomersen causes selective degradation of the apoB-100 mRNA and inhibition of protein translation. This ultimatel …
146 results